<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31265356</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>9</Issue><PubDate><Year>2019</Year></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Poliovirus antibody levels and lameness among individuals in three regions of Ghana.</ArticleTitle><Pagination><StartPage>2050</StartPage><EndPage>2059</EndPage><MedlinePgn>2050-2059</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2019.1637235</ELocationID><Abstract><AbstractText><b>Introduction</b>: Ghana recorded the last case of poliomyelitis caused by wild poliovirus in 2008 and the country was declared polio-free in 2015. Polio-neutralizing-antibody levels in the population of three geographically representative regions of Ghana was determined, to identify possible immunity gaps. <b>Methods</b>: Cross-sectional, hospital (1-70&#xa0;years old) and school (primary, 1-15&#xa0;years old)-based studies were undertaken in three regions in 2016. Individuals who visited the three teaching hospitals of the regions and were referred for haematology investigations were invited to participate in our study. Neutralizing-antibody titers to polio serotypes P1, P2, and P3 were assayed by WHO-standards. Antibody titers of &#x2265;8 were considered protective. In the school lameness survey, clinical and epidemiological data were obtained from parents and their lamed children. Bivariate and multivariate analyses were conducted on subject characteristics, to assess potential factors for failure to seroconvert. <i>P</i>-values &lt; 0.05 were considered statistically significant. <b>Results</b>: Neutralizing-antibodies against poliovirus types 1, 2 and 3 were detected in 86% (264/307), 84% (258/307) and 75% (230/307) of the samples, respectively. Overall, 60.1% (185/307) were seropositive for the three polio serotypes and 2.9% (9/307) were seronegative. Polio neutralizing-antibodies (P1and P2) decreased with age (<i>p</i>&#xa0;&lt;&#xa0;.001). Low seroprevalence of polio-neutralizing-antibodies was significantly associated with low school attendance of mothers (<i>p</i>&#xa0;&lt;&#xa0;.001). Prevalence of residual paralysis was &lt;1.0/1,000 among the school children. <b>Conclusion</b>: Our study population is moderately protected against the three poliovirus serotypes. However, immunity appears to be lower with a higher age and low mother's education. This may suggest the need for young-adult booster-dose to minimize the risk of wild poliovirus infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Opare</LastName><ForeName>Joseph Kwadwo Larbi</ForeName><Initials>JKL</Initials><AffiliationInfo><Affiliation>Ghana Field Epidemiology and Laboratory Training Program, School of Public Health, University of Ghana , Accra , Ghana.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, School of Public Health, University of Ghana , Accra , Ghana.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Second Year of life Project , Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Odoom</LastName><ForeName>John Kofi</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Virology, Noguchi Memorial Institute of Medical Research Ghana, University of Ghana , Accra , Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akweongo</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, School of Public Health, University of Ghana , Accra , Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Afari</LastName><ForeName>Edwin Andrew</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Ghana Field Epidemiology and Laboratory Training Program, School of Public Health, University of Ghana , Accra , Ghana.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, School of Public Health, University of Ghana , Accra , Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pappoe</LastName><ForeName>Matilda</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, School of Public Health, University of Ghana , Accra , Ghana.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005843" MajorTopicYN="N">Geography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005869" MajorTopicYN="N" Type="Geographic">Ghana</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009069" MajorTopicYN="N">Movement Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="N">Poliomyelitis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065288" MajorTopicYN="N">Serogroup</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Ghana</Keyword><Keyword MajorTopicYN="N">Poliomyelitis</Keyword><Keyword MajorTopicYN="N">neutralizing antibodies</Keyword><Keyword MajorTopicYN="N">polio-immunity</Keyword><Keyword MajorTopicYN="N">seroprevalence</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>7</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31265356</ArticleId><ArticleId IdType="pmc">PMC6773404</ArticleId><ArticleId IdType="doi">10.1080/21645515.2019.1637235</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Roberts L. Infectious disease. Polio outbreak breaks the rules. Science. 2010;330(6012):1730&#x2013;31. doi:10.1126/science.330.6012.1730.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.330.6012.1730</ArticleId><ArticleId IdType="pubmed">21205642</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO 
[accessed 2019 January]
http://polioeradication.org/polio-today/polio-now/.</Citation></Reference><Reference><Citation>Ghana Health Service (GHS) Disease Surveillance Division. Annual report. 2017.</Citation></Reference><Reference><Citation>Reinheimer C, Friedrichs IMK, Rabenau HF, Doerr WH. Deficiency of immunity to poliovirus type 3: a lurking danger. BMC Infect Dis. 2012;12:685&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3298481</ArticleId><ArticleId IdType="pubmed">22280025</ArticleId></ArticleIdList></Reference><Reference><Citation>Philippa MB, White JG. Prevalence of antibody to poliovirus in England and Wales 1984-6. Br Med J (Clin Res Ed). 1986. November 1;293(6555):1153&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1341857</ArticleId><ArticleId IdType="pubmed">3021273</ArticleId></ArticleIdList></Reference><Reference><Citation>Frantzidou F, Diza E, Halkia D, Antoniadis A. A seroprevalence study of poliovirus antibody in the population of northern Greece. Copyright by the European society of clinical microbiology and infectious diseases. CMI. 2004;11:63&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">15649308</ArticleId></ArticleIdList></Reference><Reference><Citation>Giwa FJ, Olayinka AT, Ogunshola FT. Seroprevalence of poliovirus antibodies amongst children in Zaria, Northern Nigeria. Vaccine. 2012. November 6;30(48):6759&#x2013;65. doi:10.1016/j.vaccine.2012.09.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.09.023</ArticleId><ArticleId IdType="pubmed">23000220</ArticleId></ArticleIdList></Reference><Reference><Citation>Iliyasu Z, Nwaze E, Verma H, Mustapha AO, Weldegebriel G, Gasasira A, Wannemuehler KA, Pallansch MA, Gajida AU, Pate M, et al. Survey of poliovirus antibodies in Kano, Northern Nigeria. Vaccine. 2014;32:1414&#x2013;20. doi:10.1016/j.vaccine.2013.08.060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.08.060</ArticleId><ArticleId IdType="pubmed">24041545</ArticleId></ArticleIdList></Reference><Reference><Citation>Habib MA, Soofi S, Ali N, Sutter RW, Pallansch MH, Qureshi H, Akhtar T, Molodecky NA, Okayasu H, Zulfiqar A, et al. A study evaluating poliovirus antibodies and risk factors associated with polio seropositivity in low socioeconomic areas of Pakistan. Vaccine. 2013. April 8;31(15):1987&#x2013;93. doi:10.1016/j.vaccine.2013.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.02.003</ArticleId><ArticleId IdType="pubmed">23429005</ArticleId></ArticleIdList></Reference><Reference><Citation>HaiBo W, Hui C, Zheng RD. Seroprevalence of antipolo antibodies among children. J ASM. 2013;Org. (20).</Citation></Reference><Reference><Citation>Lapinleimu K. Elimination of poliomyelitis in Finland. Rev Infect Dis. 1984;6:S457&#x2013;S460.</Citation><ArticleIdList><ArticleId IdType="pubmed">6330841</ArticleId></ArticleIdList></Reference><Reference><Citation>Alleman MM, Wannemuehler KA, Weldon WC, Kabuayi JP, Ekofo F, Edidi S, Mulumba A, Mbule A, Ntumbannji RN, Coulibaly T, et al. Factors contributing to outbreaks of wild poliovirus type 1 infection involving persons aged &#x2265;15 years in the Democratic Republic of the Congo, 2010&#x2013;2011, informed by a pre-outbreak poliovirus immunity assessment. J Infect Dis. 2014. November 1;210(Suppl 1):S62&#x2013;S73. doi:10.1093/infdis/jiu282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu282</ArticleId><ArticleId IdType="pubmed">25316879</ArticleId></ArticleIdList></Reference><Reference><Citation>de Miranda MP, Gomes MC, de Andrade HR. Seroprevalence of antibodies to poliovirus in individuals living in Portugal, 2002. Euro Surveill. 2007. September;12(9):E070913.4.</Citation><ArticleIdList><ArticleId IdType="pubmed">17991403</ArticleId></ArticleIdList></Reference><Reference><Citation>Calderon-Margalit R1, Sofer D, Gefen D, Lewis M, Shulman L, Mendelson E, Swartz TA, Shohat T. Immune status to poliovirus among immigrant workers in Israel. Prev Med. 2005. June;40(6):685&#x2013;89. doi:10.1016/j.ypmed.2004.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ypmed.2004.09.008</ArticleId><ArticleId IdType="pubmed">15850865</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholas DD, Kratzer JH, Ofosu-Amaah S, Belcher DW. Is poliomyelitis a serious problem in developing countries? The Danfa experience. Br Med J. 1977;1:1009&#x2013;12. doi:10.1136/bmj.1.6067.1009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.1.6067.1009</ArticleId><ArticleId IdType="pmc">PMC1605917</ArticleId><ArticleId IdType="pubmed">856396</ArticleId></ArticleIdList></Reference><Reference><Citation>Ofosu-Amaah S, Kratzer J, Nicholas DD. Is poliomyelitis a serious problem in developing countries? Lameness in Ghanaian schools. Br Med J. 1977;1:1012&#x2013;14. doi:10.1136/bmj.1.6067.1012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.1.6067.1012</ArticleId><ArticleId IdType="pmc">PMC1605957</ArticleId><ArticleId IdType="pubmed">856397</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization Expanded programme on immunization-Burma. WHO Weekly Epidemiol Rec. 1977;52:145&#x2013;46.</Citation></Reference><Reference><Citation>World Health Organization Survey for residual paralysis-Egypt. WHO Weekly Epidemiol Rec. 1977;52:269&#x2013;71.</Citation></Reference><Reference><Citation>World Health Organization Expanded programme on immunization- Philippines. WHO Weekly Epidemiol Rec. 1978;53:144&#x2013;46.</Citation></Reference><Reference><Citation>World Health Organization Expanded programme on immunization, poliomyelitis in Indonesia. WHO Weekly Epidemiol Rec. 1979;54:177&#x2013;78.</Citation></Reference><Reference><Citation>World Health Organization Expanded programme on immunization, poliomyelitis in Thailand. WHO Weekly Epidemiol Rec. 1979;54:202&#x2013;03.</Citation></Reference><Reference><Citation>Pacho N, Amela C, De Ory F. Age-specific seroprevalence of poliomyelitis, diphtheria and tetanus antibodies in Spain. Epidemiol Infect. 2002;129:535&#x2013;41. doi:10.1017/S0950268802007781.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268802007781</ArticleId><ArticleId IdType="pmc">PMC2869915</ArticleId><ArticleId IdType="pubmed">12558336</ArticleId></ArticleIdList></Reference><Reference><Citation>Jee YM, Cheon DS, Kim KS, Lee SH, Yoon JD, Lee SW, Go U, Yang BK, Ki MR, Choi BY, et al. A seroprevalence study of poliovirus antibody among primary school children in Korea. Epidemiol Infect. 2004;132:351&#x2013;55. doi:10.1017/s0950268804002171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/s0950268804002171</ArticleId><ArticleId IdType="pmc">PMC2870112</ArticleId><ArticleId IdType="pubmed">15061511</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace T, Gregory S, Aaron T, William C, Oberste SM. Seroprevalence of poliovirus antibodies in the United States population, 2009&#x2013;2010. BMC Public Health. 2016;16:72. doi:10.1186/s12889-016-3386-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-016-3386-1</ArticleId><ArticleId IdType="pmc">PMC4974751</ArticleId><ArticleId IdType="pubmed">27492318</ArticleId></ArticleIdList></Reference><Reference><Citation>Baba MM, Haruna BA, Ogunmola O, Ambe JP, Shidali NN, Oderinde B, Marcello A, Talle M. A survey for neutralizing antibodies to the three types of poliovirus among children in Maiduguri, Nigeria. J Med Virol. 2012. April;84(4):691&#x2013;96. doi:10.1002/jmv.23228.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.23228</ArticleId><ArticleId IdType="pubmed">22337311</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghana Health Service (GHS) a polio-free country. Disease Surveillance Division Report. 2015.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention Imported wild poliovirus causing poliomyelitis - Bulgaria. MMWR Morb Mortal Wkly Rep. 2001;50(46):1033&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">11902348</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention Resurgence of wild poliovirus type 1 transmission and consequences of importation - 21 countries, 2002&#x2013;2005. MMWR Morb Mortal Wkly Rep. 2006;55(6):145&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">16484977</ArticleId></ArticleIdList></Reference><Reference><Citation>Grassly NC, Fraser C, Wenger J. New strategies for the eradication of polio India. Science. 2006;314:1150&#x2013;53. doi:10.1126/science.1130388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1130388</ArticleId><ArticleId IdType="pubmed">17110580</ArticleId></ArticleIdList></Reference><Reference><Citation>Grassly NC, Wenger J, Durrani S. Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control study. Lancet. 2007;369:1356&#x2013;62. doi:10.1016/S0140-6736(07)60531-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(07)60531-5</ArticleId><ArticleId IdType="pubmed">17448821</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control Public health dispatch. An outbreak of poliomyelitis-dominican republic and haiti. MMWR. 2000;49:1049&#x2013;103.</Citation></Reference><Reference><Citation>Anderson RM. The concept of herd immunity and the design of community-based immunization programmes. Vaccine. 1992;10:928&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">1471414</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutter RW, Kew O, Cochi SL. Poliovirus vaccines&#x2014;live In: Plotkin SA, Orenstein WA, editors. Vaccines. Vol. ch26 4th ed. Philadelphia (PA): W.B.Saunders; 2004.</Citation></Reference><Reference><Citation>El-Sayed N, Al-Jorf S, Hennessey KA, Salama M, Watkins MA, Abdel Wahab JA, Pallansch MA, Gary H, Wahdan MH, Sutter RW. Survey of poliovirus antibodies during the final stage of polio eradication in Egypt. Vaccine. 2007;25(27):5062&#x2013;70. doi:10.1016/j.vaccine.2007.04.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2007.04.022</ArticleId><ArticleId IdType="pubmed">17543428</ArticleId></ArticleIdList></Reference><Reference><Citation>HaiBo W, Cui H, Zheng RD. Seroprevalence of antipolo antibodies among children. J ASM. 2013;Org. (20):33.</Citation></Reference><Reference><Citation>Frantzidou F, Diza E, Halkia D, Antoniadis A. A seroprevalence study of poliovirus antibody in the population of Northern Greece. Clin Microbiol Infect. 2005;11:68&#x2013;71. doi:10.1111/j.1469-0691.2004.00998.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-0691.2004.00998.x</ArticleId><ArticleId IdType="pubmed">15649308</ArticleId></ArticleIdList></Reference><Reference><Citation>Diedrich S, Hermann C, Eckart S. Immunity status against poliomyelitis in Germany: determination of cut-off values in International Units. BMC Infect Dis. 2002;2:2. doi:10.1186/1471-2334-2-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2334-2-2</ArticleId><ArticleId IdType="pmc">PMC101379</ArticleId><ArticleId IdType="pubmed">11943068</ArticleId></ArticleIdList></Reference><Reference><Citation>Akoua-Koffi G, Thonnon J, Kouassi-Renaud M, Dosso M, Ehouman A. Post-vaccination anti-poliomyelitis seroprevalence in an urban setting in Abidjan. Bull Soc Pathol Exot. 1995;88:117&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">8555765</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshpande JM, Kamat JR, Rao VK, Nadkarni SS, Kher AS, Saigaokar SD. Prevalence of antibodies and enteroviruses excreted by healthy children in Bombay. Indian J Med Res. 1995;101:50&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">7729847</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassioni LE, Barakat I, Nasr E, de Gourville EM, Hovi T, Blomqvist S, Burns C, Stenvik M, Gary H, Kew OM, et al. Prolonged detection of indigenous wild polioviruses in sewage from communities in Egypt. Am J Epidemiol. 2003;158(8). doi:10.1093/aje/kwg202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwg202</ArticleId><ArticleId IdType="pubmed">14561671</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization Progress towards global interruption of wild poliovirus transmission. Wkly Epidemiol Rec. 2012;87:195&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">24340401</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghana Health Service (GHS) Expanded Programme on Immunization. Half Year Report.2016.</Citation></Reference><Reference><Citation>P&#xed;rez MC, Olivera I, Diabarboure H, Montano A, Bara&#xf1;ano R, Bad&#xed;a F, Bonnet MC. Seroprevalence of anti-polio antibodies in a population 7 months to 39 years of age in Uruguay: implications for future polio vaccination strategies. Vaccine. 2009;27:2689&#x2013;94. doi:10.1016/j.vaccine.2009.02.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2009.02.042</ArticleId><ArticleId IdType="pubmed">19428880</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoub BD, Blackburn NK, McAnerney JM. Seroprevalence to polio in personnel at a virology institute. J Infect. 2001;43(2):128&#x2013;31. doi:10.1053/jinf.2001.0867.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/jinf.2001.0867</ArticleId><ArticleId IdType="pubmed">11676519</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams JO, David-West TS. Poliovirus antibody in children from a paediatric hospital in Ibadan, Nigeria. Rev Roum Virol. 1990;41:129&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">2176534</ArticleId></ArticleIdList></Reference><Reference><Citation>Grassly NC. Waning intestinal immunity after vaccination with oral poliovirus vaccines in India. J Infect Dis. 2012;205(10):1554&#x2013;61. doi:10.1093/infdis/jis213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jis213</ArticleId><ArticleId IdType="pubmed">22448007</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization 
Polio. 2013. 
[accessed 2018 July]
http://www.who.int/mediacentre/factsheets/fs114/en/index.html.</Citation></Reference><Reference><Citation>Ofosu-Amaah S, Kratzer J, Nicholas DD. Is poliomyelitis a serious problem in developing countries?&#x201d; Lameness in Ghanaian schools. Br Med J. 1977;1:1012&#x2013;14. doi:10.1136/bmj.1.6067.1012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.1.6067.1012</ArticleId><ArticleId IdType="pmc">PMC1605957</ArticleId><ArticleId IdType="pubmed">856397</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghana Health Service (GHS) Expanded programme on immunization. Annual Report. 2018.</Citation></Reference><Reference><Citation>Opare JKL, Odoom JK, Akweongo P, Afari EA. lameness among individuals in three regions of Ghana. 2017. unpublished.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6773404</ArticleId><ArticleId IdType="pubmed">31265356</ArticleId></ArticleIdList></Reference><Reference><Citation>Boche R. La poliomyelite au Cameroun. Revue d&#x2019;epidemiologie, medecinesociale et santepublique. 1973;21:79.</Citation></Reference><Reference><Citation>Guyer B. The seroepidemiology of poliovirus in Yaounde, Cameroon: a survey following one year of immunization. J Trop Pediatr. 1976;27:140&#x2013;43. doi:10.1093/tropej/27.3.140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/tropej/27.3.140</ArticleId></ArticleIdList></Reference><Reference><Citation>Heymann L, Virginia DFM, Lichnevski GKM, Flaubert M. Estimation of incidence of poliomyelitis by three survey methods in different regions of the United Republic of Cameroon. Bull World Health Organ. 1983;61(3):501&#x2013;07. World Health Organization.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2536106</ArticleId><ArticleId IdType="pubmed">6603923</ArticleId></ArticleIdList></Reference><Reference><Citation>Collingham KE, Pollock TM, Roebuck MO. Paralytic poliomyelitis in England and Wales 1976-7. Lancet. 1978. May 6;1(8071):976&#x2013;77. doi:10.1016/s0140-6736(78)90360-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(78)90360-4</ArticleId><ArticleId IdType="pubmed">76901</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotti SB, Satpathy SK, Mehta SP. Prevalence of paralytic poliomyelitis in Pondicherry, South India. Epidemioll Commun Health. 1982;36:279&#x2013;81. doi:10.1136/jech.36.4.279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jech.36.4.279</ArticleId><ArticleId IdType="pmc">PMC1052233</ArticleId><ArticleId IdType="pubmed">7166684</ArticleId></ArticleIdList></Reference><Reference><Citation>Horstmann D. Acute poliomyelitis relation of physical activity at the time of onset to the course of the disease. J Am Med Assoc. 1950;142(4):236&#x2013;41. doi:10.1001/jama.1950.02910220016004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1950.02910220016004</ArticleId><ArticleId IdType="pubmed">15400610</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochran WG. Sampling techniques. 3rd ed. New York (NY): John Wiley and Sons; 1977.</Citation></Reference><Reference><Citation>Ghana Education Service (GES) 
Enrolment in Schools. Education Management Information System (EMIS) Ghana. 2016. 
http://www.ghanaeducationdata.com.</Citation></Reference><Reference><Citation>WHO Manual the virological investigation of polio. Global programme for vaccines and immunization. Expanded programme on immunization. Geneva: WHO; 1997.</Citation></Reference><Reference><Citation>Laforce FM, Lichnevski MS, Keja J, Henderson RH. Clinical survey techniques to estimate prevalence and annual incidence of poliomyelitis in developing countries. Bull World Health Organ. 1980;58:609&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2395925</ArticleId><ArticleId IdType="pubmed">6969133</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>